BioCorRx Inc.
Close on Oct 19, 2026
- Market cap
- $7.30M
- P/E (TTM)
- –
- Dividend yield
- –
About BioCorRx
Services-Specialty Outpatient Facilities, NEC, SIC 8093
BioCorRx Inc. develops and supplies medical solutions for substance use disorders and weight management. The company operates primarily through addiction treatment programs and clinical-stage pharmaceutical development. Its core offerings include the Beat Addiction Recovery Program, which combines proprietary cognitive behavioral therapy modules, mobile peer support, and physician-prescribed medication, and the UnCraveRx Weight Loss Program, which provides medication-assisted support alongside wellness coaching. Through its majority-owned pharmaceutical subsidiary, the company distributes Lucemyra for opioid withdrawal and conducts clinical research on BICX104, an implantable naltrexone pellet. BioCorRx provides its treatment programs and products to licensed healthcare providers, independent physicians, rehabilitation facilities, and commercial distributors.
The company is incorporated in Nevada and conducts its business activities across the United States, including licensing arrangements in states such as Connecticut. Its operational scale includes approximately 12 licensed healthcare providers that offer the recovery program and about 8 providers offering the weight loss program. The provided text does not identify the location of the company's corporate headquarters.
Summary of the business section of BioCorRx's latest annual report, written by StockData.
Company profile
Company
- Legal name
- BioCorRx Inc.
- Founded
- 2008
- Headquarters
- Anaheim, CA
- Address
- 2390 East Orangewood Avenue, Suite 570 92806
- Phone
- (714) 462-4880
- Employees
- 3, Dec 31, 2012
- Industry
- Services-Specialty Outpatient Facilities, NEC
- Fiscal year ends
- December 31
- Auditor
- M&K CPAS, PLLC, Woodlands, TX
Stock & identifiers
- Ticker
- BICX
- Exchange
- OTC
- IPO date
- Aug 31, 2010
- Shares outstanding
- 30M, Aug 14, 2026
- Public float
- $2.86M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-100 reverse, Apr 16, 2019; 1-for-100 reverse, Jan 22, 2019
- SEC CIK
- 1443863
- EIN
- 90-0967447
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Lourdes Felix | CEO and CFO, Director | 843,578 |
| Louis C. Lucido | President, Director | 2,788,219 |
Corporate history
Events identified from SEC filings